Anhui Huangshan Capsule Co Ltd

Anhui Huangshan Capsule Co Ltd maintains a strong liquidity position, with a current ratio of 3.13, indicating the company can cover its short-term liabilities more than three times over. However, the company reported negative operating cash flow of -11,399,310 CNY and capital expenditures of -9,884,090 CNY, suggesting ongoing investment in operations and potential cash flow constraints. The company's debt-to-equity ratio is 0.01, reflecting a conservative capital structure with minimal leverage.

In terms of profitability, the company's return on equity (ROE) is 1.59%, and return on assets (ROA) is 1.34%, both below the typical thresholds for high-performing pharmaceutical firms. These metrics suggest the company is generating modest returns relative to its equity and asset base. Gross profit of 29,424,250 CNY and operating income of 16,885,080 CNY indicate a relatively narrow margin structure, which may limit its ability to absorb cost increases or invest in innovation.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes, particularly in the pharmaceutical sector. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets or product lines.

Looking ahead, the company's growth trajectory is uncertain. While the current fiscal year shows a revenue of 116,857,450 CNY, there is no disclosed outlook for the next fiscal year. The company's capital expenditures suggest ongoing investment, but the negative operating cash flow raises questions about the sustainability of these investments without external financing. The company's net income of 14,355,300 CNY is modest relative to its asset base, and there is no indication of significant revenue growth in the near term.

The company faces moderate liquidity risk, as its operating cash flow is negative and its net cash position is negative after subtracting total debt. The risk of dilution is low, with no significant changes in shares outstanding between basic and diluted shares. However, the company's conservative capital structure may limit its ability to raise capital for expansion or innovation. The absence of recent filings or transcripts limits the ability to assess management's strategic direction or response to market conditions.

Recent financial data does not include any specific events or filings that would indicate significant changes in the company's operations or strategy. The lack of disclosed recent events or transcripts suggests limited transparency into the company's management decisions and future plans.

Anhui Huangshan Capsule Co Ltd (002817.SZ) has undergone a formal classification update, with its economic sector now identified as Healthcare and its primary activity designated as Pharmaceuticals. This structural clarification establishes the company’s operational context within the broader healthcare industry, providing a clearer framework for sector-specific analysis. Concurrently, the company’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, suggesting limited immediate pressure from equity issuance or similar capital structure changes. This assessment offers a baseline for evaluating the stability of shareholder value against potential dilution events. Liquidity risk, however, is classified as medium, indicating a moderate level of concern regarding the company’s ability to meet short-term financial obligations. This rating highlights a key area of financial monitoring, distinguishing it from the lower dilution risk and suggesting that cash flow management remains a relevant factor for investors. These updates reflect a comprehensive review of the company’s fundamental attributes, moving from unclassified status to defined sector and risk parameters. The combination of a low dilution risk and medium liquidity risk provides a nuanced view of the company’s financial health, while the Healthcare/Pharmaceutical classification anchors its market positioning. No analyst coverage, index memberships, or significant holder data are currently recorded in the available profile. [doc:002817.sz-ha-financials]

Net income surged 31.9% year-over-year to CNY 65 million, demonstrating strong profitability growth despite revenue headwinds.

Free cash flow increased 40.6% year-over-year to CNY 79.2 million, highlighting robust cash generation capabilities.

The company maintains a negligible debt-to-equity ratio of 0.01, far below the cohort median of 0.18.

Revenue declined 2.8% year-over-year to CNY 460.4 million, signaling weakening top-line growth momentum.

Cash conversion ratio of -0.79 places the company in the bottom quartile of its peer group.

Return on assets of 1.3% suggests limited ability to generate profits from total asset base.

Medium liquidity risk flags potential challenges in meeting short-term financial obligations compared to peers.